Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy
Cancer immunotherapy, which suppresses cancer progression by activating the anti-cancer immunity of patients, shows utility in treating multiple types of cancers. Immunogenic cell death (ICD) induced by most clinical treatment modalities plays a critical role in promoting cancer immunotherapy by rel...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-03-01
|
| Series: | Asian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087620303846 |
| _version_ | 1819320444249964544 |
|---|---|
| author | Yajie Sun Xiangru Feng Chao Wan Jonathan F. Lovell Honglin Jin Jianxun Ding |
| author_facet | Yajie Sun Xiangru Feng Chao Wan Jonathan F. Lovell Honglin Jin Jianxun Ding |
| author_sort | Yajie Sun |
| collection | DOAJ |
| description | Cancer immunotherapy, which suppresses cancer progression by activating the anti-cancer immunity of patients, shows utility in treating multiple types of cancers. Immunogenic cell death (ICD) induced by most clinical treatment modalities plays a critical role in promoting cancer immunotherapy by releasing tumor-associated antigens and neoantigens and exposing “danger signals” to stimulate immune cells. This comment article presents the different roles of nanoparticles in various treatment modalities of cancers, including chemotherapy, radiotherapy, photodynamic and photothermal therapies, and therapy with radiated tumor cell-released nanoparticles, which often activate anti-cancer immunological effects by inducing ICD of cancer cells, and highlights the challenges and opportunities of ICD-related cancer immunotherapy in the clinic. |
| first_indexed | 2024-12-24T11:19:40Z |
| format | Article |
| id | doaj.art-20d629a3f6994188b5ea9ac6f27698bd |
| institution | Directory Open Access Journal |
| issn | 1818-0876 |
| language | English |
| last_indexed | 2024-12-24T11:19:40Z |
| publishDate | 2021-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-20d629a3f6994188b5ea9ac6f27698bd2022-12-21T16:58:16ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762021-03-01162129132Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapyYajie Sun0Xiangru Feng1Chao Wan2Jonathan F. Lovell3Honglin Jin4Jianxun Ding5Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaChina Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, ChinaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Biomedical Engineering, University at Buffalo, State University of New York. Buffalo, New York 14260, USAUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Corresponding author.China Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, ChinaCancer immunotherapy, which suppresses cancer progression by activating the anti-cancer immunity of patients, shows utility in treating multiple types of cancers. Immunogenic cell death (ICD) induced by most clinical treatment modalities plays a critical role in promoting cancer immunotherapy by releasing tumor-associated antigens and neoantigens and exposing “danger signals” to stimulate immune cells. This comment article presents the different roles of nanoparticles in various treatment modalities of cancers, including chemotherapy, radiotherapy, photodynamic and photothermal therapies, and therapy with radiated tumor cell-released nanoparticles, which often activate anti-cancer immunological effects by inducing ICD of cancer cells, and highlights the challenges and opportunities of ICD-related cancer immunotherapy in the clinic.http://www.sciencedirect.com/science/article/pii/S1818087620303846Immunogenic cell deathNanoparticleNanoformulationImmunotherapyMultimodal cancer therapy |
| spellingShingle | Yajie Sun Xiangru Feng Chao Wan Jonathan F. Lovell Honglin Jin Jianxun Ding Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy Asian Journal of Pharmaceutical Sciences Immunogenic cell death Nanoparticle Nanoformulation Immunotherapy Multimodal cancer therapy |
| title | Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy |
| title_full | Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy |
| title_fullStr | Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy |
| title_full_unstemmed | Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy |
| title_short | Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy |
| title_sort | role of nanoparticle mediated immunogenic cell death in cancer immunotherapy |
| topic | Immunogenic cell death Nanoparticle Nanoformulation Immunotherapy Multimodal cancer therapy |
| url | http://www.sciencedirect.com/science/article/pii/S1818087620303846 |
| work_keys_str_mv | AT yajiesun roleofnanoparticlemediatedimmunogeniccelldeathincancerimmunotherapy AT xiangrufeng roleofnanoparticlemediatedimmunogeniccelldeathincancerimmunotherapy AT chaowan roleofnanoparticlemediatedimmunogeniccelldeathincancerimmunotherapy AT jonathanflovell roleofnanoparticlemediatedimmunogeniccelldeathincancerimmunotherapy AT honglinjin roleofnanoparticlemediatedimmunogeniccelldeathincancerimmunotherapy AT jianxunding roleofnanoparticlemediatedimmunogeniccelldeathincancerimmunotherapy |